Since the 50s in the last century, cancer gradually became one of the priorities in public health, and new anticancer drugs have been studied in this field. Due to lack of proper guidelines in the early days, the development of new anticancer drugs was slow and difficult. Only after the mid of 80s, clinical trials were started according to GCP principles designed by the Bureau of Drugs under Ministry of Health. Several effective new anticancer drugs were tested and available in the hospital for cancer patients. Since the establishment of State Food and Drug Administration (SFDA ten years ago, number of clinical trials reached more than 100 every year in recent 5 years, and some of them were global multi-centers trials. We have developed several new drugs such as endostatin (Endostar) and Rg3 as anti-angiogenesis agents, and the active components from Chinese medicinal herbs are also marketed such as Kanglaite and -elemene. New targeted drugs, such as Eketinib and Nimotuzumab, are currently under clinical trial. There are 12 new drugs or approaches developed in China, which have improved the clinical practice and bring benefit to cancer patients in the last 5 decades. Several basic principles of traditional Chinese medicine are integrated into the individualization of clinical oncology practice such as "same disease different treatments" and "different diseases same treatment". It is concluded that the development of new anticancer drugs should be one of our priorities and innovation in clinical oncology can save life.
|Number of pages||6|
|Journal||Chinese Journal of New Drugs|
|State||Published - 2009|
- GCP guidelines
- New anticancer drugs